Summit Partners Public Asset Management LLC Sells 126,122 Shares of RxSight, Inc. (NASDAQ:RXST)

Summit Partners Public Asset Management LLC trimmed its position in RxSight, Inc. (NASDAQ:RXST) by 15.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 687,711 shares of the company’s stock after selling 126,122 shares during the quarter. RxSight accounts for approximately 1.1% of Summit Partners Public Asset Management LLC’s holdings, making the stock its 21st biggest holding. Summit Partners Public Asset Management LLC’s holdings in RxSight were worth $33,994,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of RxSight by 8.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,818 shares of the company’s stock valued at $3,402,000 after acquiring an additional 5,266 shares during the period. MetLife Investment Management LLC grew its stake in shares of RxSight by 4.0% in the third quarter. MetLife Investment Management LLC now owns 20,525 shares of the company’s stock worth $1,015,000 after purchasing an additional 790 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in RxSight by 1.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company’s stock valued at $1,034,000 after purchasing an additional 399 shares during the period. Bank of Montreal Can raised its position in RxSight by 32.4% during the 3rd quarter. Bank of Montreal Can now owns 119,580 shares of the company’s stock valued at $5,804,000 after purchasing an additional 29,230 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in RxSight in the 3rd quarter worth approximately $605,000. 78.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RXST. Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company decreased their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus cut their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $61.63.

RxSight Trading Up 0.7 %

RXST stock opened at $46.40 on Friday. The firm has a 50 day moving average price of $48.85 and a 200-day moving average price of $52.44. RxSight, Inc. has a 52-week low of $28.88 and a 52-week high of $66.54.

Insider Activity at RxSight

In other news, insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,225,096.82. This trade represents a 6.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the transaction, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,702 shares of company stock valued at $3,059,197 in the last 90 days. Corporate insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.